Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)
Status:
Terminated
Trial end date:
2020-01-16
Target enrollment:
Participant gender:
Summary
Eligible patients have multiple myeloma with measurable disease in the blood and a targetable
soft tissue or bony lesion with radiotherapy. All eligible patients will receive
immunotherapy (Nivolumab) plus radiotherapy, 6 Gy x 5 fractions, to a targetable lesion.
Immunotherapy treatment starts with the first radiotherapy fraction. Nivolumab will be given
every 2 weeks. Patients will have specified laboratory values measured bi-monthly and
evaluated for response at 12 weeks as defined by International Myeloma Working Group
Criteria. Patients will continue to receive their respective immunotherapy until disease
progression or dose limiting toxicity is reached.